# A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

> **NCT03717415** · PHASE1,PHASE2 · TERMINATED · sponsor: **Deciphera Pharmaceuticals, LLC** · enrollment: 70 (actual)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumor

## Interventions

- **DRUG:** Rebastinib
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03717415
- **Lead sponsor:** Deciphera Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-02
- **Primary completion:** 2022-05-01
- **Final completion:** 2022-11-01
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** Development program terminated.
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03717415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03717415, "A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03717415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*